Jeffrey W. Tyner

Jeffrey W. Tyner

Auto-generated profile, based on publicly available information

Jeffrey W. Tyner

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
Joseph KhouryJoseph Khoury
Joseph Khoury
ESEric Solary
Eric Solary
OAOussama Abla
Oussama Abla
YAYassmine Akkari
Yassmine Akkari
RARita Alaggio
Rita Alaggio
AHAndreas Hochhaus
Andreas Hochhaus
The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.

1 November 2009 in Cancer Cell
Verified
Journal Article
Closed access
TOThomas O'HAre
Thomas O'HAre
WSWilliam C. Shakespeare
William C. Shakespeare
XZXiaotian Zhu
Xiaotian Zhu
CEChristopher A. Eide
Christopher A. Eide
VRVictor M. Rivera
Victor M. Rivera
TCTim Clackson
Tim Clackson

13 January 2011 in Blood
Verified
Journal Article
Open access
PDF file
BLBrian J. Lannutti
Brian J. Lannutti
SMSarah A. Meadows
Sarah A. Meadows
SHSarah E. M. Herman
Sarah E. M. Herman
AKAdam Kashishian
Adam Kashishian
BSBart Steiner
Bart Steiner
NGNeill A. Giese
Neill A. Giese
Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from cell surface receptors known to promote malignant B-cell proliferation and survival. This provides a rationale for the development of small molecule inhibitors that selectively target p110δ as a treatment approach for patients with B-cell malignancies. We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective and potent p110δ small molecule inhibitor (half-maximal effective concentration [EC50] = 8nM). Using tumor cell lines and primary patient samples representing multiple B-cell malignancies, we have demonstrated that constitutive phosphatidylinositol-3-kinase pathway activation is p110δ-dependent. CAL-101 blocked constitutive phosphatidylinositol-3-kinase signaling, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and caspase cleavage and an induction of apoptosis. These effects have been observed across a broad range of immature and mature B-cell malignancies, thereby providing a rationale for the ongoing clinical evaluation of CAL-101.

9 May 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JMJulia E. Maxson
Julia E. Maxson
JGJason Gotlib
Jason Gotlib
DPDaniel A. Pollyea
Daniel A. Pollyea
AFAngela Fleischman
Angela Fleischman
AAAnupriya Agarwal
Anupriya Agarwal
JTJeffrey W. Tyner
Jeffrey W. Tyner
The molecular causes of many hematologic cancers remain unclear. Among these cancers are chronic neutrophilic leukemia (CNL) and atypical (BCR-ABL1–negative) chronic myeloid leukemia (CML), both of which are diagnosed on the basis of neoplastic expansion of granulocytic cells and exclusion of genetic drivers that are known to occur in other myeloproliferative neoplasms and myeloproliferative–myelodysplastic overlap neoplasms. To identify potential genetic drivers in these disorders, we used an integrated approach of deep sequencing coupled with the screening of primary leukemia cells obtained from patients with CNL or atypical CML against panels of tyrosine kinase–specific small interfering RNAs or small-molecule kinase inhibitors. We validated candidate oncogenes using in vitro transformation assays, and drug sensitivities were validated with the use of assays of primary-cell colonies. We identified activating mutations in the gene encoding the receptor for colony-stimulating factor 3 (CSF3R) in 16 of 27 patients (59%) with CNL or atypical CML. These mutations segregate within two distinct regions of CSF3R and lead to preferential downstream kinase signaling through SRC family–TNK2 or JAK kinases and differential sensitivity to kinase inhibitors. A patient with CNL carrying a JAK-activating CSF3R mutation had marked clinical improvement after the administration of the JAK1/2 inhibitor ruxolitinib. Mutations in CSF3R are common in patients with CNL or atypical CML and represent a potentially useful criterion for diagnosing these neoplasms. (Funded by the Leukemia and Lymphoma Society and others.)

18 May 2008 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
EKEdy Y Kim
Edy Y Kim
JBJohn T Battaile
John T Battaile
APAnand C Patel
Anand C Patel
YYYingjian You
Yingjian You
EAEugene Agapov
Eugene Agapov
MHMichael J Holtzman
Michael J Holtzman

21 July 2022 in Cancer Cell
Verified
Journal Article
Open access
DBDaniel Bottomly
Daniel Bottomly
NLNicola Long
Nicola Long
ASAnna Reister Schultz
Anna Reister Schultz
SKStephen E. Kurtz
Stephen E. Kurtz
CTCristina E. Tognon
Cristina E. Tognon
JTJeffrey W. Tyner
Jeffrey W. Tyner
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large cohort of AML patients, which facilitated discovery of functional genomic correlates. Here, we present a dataset that has been harmonized with our initial report to yield a cumulative cohort of 805 patients (942 specimens). We show strong cross-cohort concordance and identify features of drug response. Further, deconvoluting transcriptomic data shows that drug sensitivity is governed broadly by AML cell differentiation state, sometimes conditionally affecting other correlates of response. Finally, modeling of clinical outcome reveals a single gene, PEAR1, to be among the strongest predictors of patient survival, especially for young patients. Collectively, this report expands a large functional genomic resource, offers avenues for mechanistic exploration and drug development, and reveals tools for predicting outcome in AML.